What is Genetesis?
Genetesis is at the forefront of cardiac care innovation with its CardioFlux Membership program, designed to revolutionize preventive cardiac diagnostics. The company's core technology, CardioFlux, employs magnetocardiography to offer a rapid, non-invasive method for detecting functionally significant ischemia. This technology is particularly valuable for patients presenting with chest pain and for healthcare professionals seeking more efficient diagnostic tools. By optimizing hospital workflows and reducing patient wait times, Genetesis aims to elevate the standard of care in cardiac imaging and diagnostics.
How much funding has Genetesis raised?
Genetesis has raised a total of $35.9M across 5 funding rounds:
Angel/Seed
$1.2M
Series A
$7.5M
Series B
$9.2M
Debt
$508K
Series C
$17.5M
Angel/Seed (2016): $1.2M with participation from LOUD Capital and CincyTech
Series A (2018): $7.5M, investors not publicly disclosed
Series B (2020): $9.2M supported by TDK Ventures
Debt (2021): $508K featuring PPP
Series C (2022): $17.5M backed by Mithril Capital Management, CincyTech, Ohio Innovation Fund, Cercano Management, and JobsOhio companies
Key Investors in Genetesis
TDK Ventures
TDK Ventures is a venture capital firm that invests in innovative technologies and companies, often with a focus on materials science, energy, and advanced electronics, aligning with Genetesis's technology-driven approach to healthcare.
LOUD Capital
LOUD Capital is a venture capital firm focused on healthcare innovations, investing in companies that balance purpose with profit to address real-world healthcare challenges. The firm combines capital with leadership and operational support, embedding expertise directly into portfolio companies to accelerate growth and innovation.
CincyTech
CincyTech, headquartered in Cincinnati, Ohio, is a public-private seed-stage investor company. They specialize in industries such as enterprise software, business software applications, life sciences, and digital health, making them a strategic partner for a health tech company like Genetesis.
What's next for Genetesis?
The recent substantial investment in Genetesis signals a strong market validation and provides the necessary capital for scaling its operations and expanding its market reach. With a clear focus on enhancing cardiac care through advanced technology, the company is well-positioned for significant growth. Future strategic initiatives will likely involve further development of the CardioFlux platform, broader adoption by healthcare systems, and potentially exploring new applications for its diagnostic capabilities. This funding round is a critical step in solidifying Genetesis's position as a leader in the preventive cardiac care sector.
See full Genetesis company page
